Category Archives: Genetics

Epigenetics, the misunderstood science that could shed new light on ageing – The Guardian

A little over a decade ago, a clutch of scientific studies was published that seemed to show that survivors of atrocities or disasters such as the Holocaust and the Dutch famine of 1944-45 had passed on the biological scars of those traumatic experiences to their children.

The studies caused a sensation, earning their own BBC Horizon documentary and the cover of Time (I also wrote about them, for New Scientist) and no wonder. The mind-blowing implications were that DNA wasnt the only mode of biological inheritance, and that traits acquired by a person in their lifetime could be heritable. Since we receive our full complement of genes at conception and it remains essentially unchanged until our death, this information was thought to be transmitted via chemical tags on genes called epigenetic marks that dial those genes output up or down. The phenomenon, known as transgenerational epigenetic inheritance, caught the public imagination, in part because it seemed to release us from the tyranny of DNA. Genetic determinism was dead.

A decade on, the case for transgenerational epigenetic inheritance in humans has crumbled. Scientists know that it happens in plants, and weakly in some mammals. They cant rule it out in people, because its difficult to rule anything out in science, but there is no convincing evidence for it to date and no known physiological mechanism by which it could work. One well documented finding alone seems to present a towering obstacle to it: except in very rare genetic disorders, all epigenetic marks are erased from the genetic material of a human egg and sperm soon after their nuclei fuse during fertilisation. The [epigenetic] patterns are established anew in each generation, says geneticist Bernhard Horsthemke of the University of Duisburg-Essen in Germany.

Even at the time, sceptics pointed out that it was fiendishly difficult to disentangle the genetic, epigenetic and environmental contributions to inherited traits. For one thing, a person shares her mothers environment from the womb on, so that persons epigenome could come to resemble her mothers without any information being transmitted via the germline, or reproductive cells. In the past decade, the threads have become even more tangled, because it turns out that epigenetic marks are themselves largely under genetic control. Some genes influence the degree to which other genes are annotated and this shows up in twin studies, where certain epigenetic patterns have been found to be more similar in identical twins that in non-identical ones.

This has led researchers to think of the epigenome less as the language in which the environment commands the genes, and more as a way in which the genes adjust themselves to respond better to an unpredictable environment. Epigenetics is often presented as being in opposition to genetics, but actually the two things are intertwined, says Jonathan Mill, an epigeneticist at the University of Exeter. The relationship between them is still being worked out, but for geneticist Adrian Bird of the University of Edinburgh, the role of the environment in shaping the epigenome has been exaggerated. In fact, cells go to quite a lot of trouble to insulate themselves from environmental insult, he says.

Whatever that relationship turns out to be, the study of epigenetics seems to reinforce the case that its not nature versus nurture, but nature plus nurture (so genetic determinism is still dead). And whatever the contribution of the epigenome, it doesnt seem to translate across generations.

All the aforementioned researchers rue the fact that transgenerational epigenetic inheritance is still what most people think of when they hear the word epigenetics, because the past decade has also seen exciting advances in the field, in terms of the light it has shed on human health and disease. The marks that accumulate on somatic cells that is, all the bodys cells except the reproductive ones turn out to be very informative about these, and new technologies have made it easier to read them.

Different people define epigenetics differently, which is another reason why the field is misunderstood. Some define it as modifications to chromatin, the package that contains DNA inside the nuclei of human cells, while others include modifications to RNA. DNA is modified by the addition of chemical groups. Methylation, when a methyl group is added, is the form of DNA modification that has been studied most, but DNA can also be tagged with hydroxymethyl groups, and proteins in the chromatin complex can be modified too.

Researchers can generate genome-wide maps of DNA methylation and use these to track biological ageing, which as everyone knows is not the same as chronological ageing. The first such epigenetic clocks were established for blood, and showed strong associations with other measures of blood ageing such as blood pressure and lipid levels. But the epigenetic signature of ageing is different in different tissues, so these couldnt tell you much about, say, brain or liver. The past five years have seen the description of many more tissue-specific epigenetic clocks.

Mills group is working on a brain clock, for example, that he hopes will correlate with other indicators of ageing in the cortex. He has already identified what he believes to be an epigenetic signature of neurodegenerative disease. Were able to show robust differences in DNA methylation between individuals with and without dementia, that are very strongly related to the amount of pathology they have in their brains, Mill says. Its not yet possible to say whether those differences are a cause or consequence of the pathology, but they provide information about the mechanisms and genes that are disrupted in the disease process, that could guide the development of novel diagnostic tests and treatments. If a signal could be found in the blood, say, that correlated with the brain signal theyve detected, it could form the basis of a predictive blood test for dementia.

While Bird and others argue that the epigenome is predominantly under genetic control, some researchers are interested in the trace that certain environmental insults leave there. Smoking, for example, has a clear epigenetic signature. I could tell you quite accurately, based on their DNA methylation profile, if someone was a smoker or not, and probably how much they smoked and how long they had smoked for, says Mill.

James Flanagan of Imperial College London is among those who are exploiting this aspect of the epigenome to try to understand how lifestyle factors such as smoking, alcohol and obesity shape cancer risk. Indeed, cancer is the area where there is most excitement in terms of the clinical application of epigenetics. One idea, Flanagan says, is that once informed of their risk a person could make lifestyle adjustments to reduce it.

Drugs that remodel the epigenome have been used therapeutically in those already diagnosed with cancer, though they tend to have bad side-effects because their epigenetic impact is so broad. Other widely prescribed drugs that have few side-effects might turn out to work at least partly via the epigenome too. Based on the striking observation that breast cancer risk is more than halved in diabetes patients who have taken the diabetes drug metformin for a long time, Flanagans group is investigating whether this protective effect is mediated by altered epigenetic patterns.

Meanwhile, the US-based company Grail which has just been bought, controversially, by DNA sequencing giant Illumina has come up with a test for more than 50 cancers that detects altered methylation patterns in DNA circulating freely in the blood.

Based on publicly available data on its false-positive and false-negative rates, the Grail test looks very promising, says Tomasz K Wojdacz, who studies clinical epigenetics at the Pomeranian Medical University in Szczecin, Poland. But more data is needed and is being collected now in a major clinical trial in the NHS. The idea is that the test would be used to screen populations, identifying individuals at risk who would then be guided towards more classical diagnostic procedures such as tissue-specific biopsies. It could be a gamechanger in cancer, Wojdacz thinks, but it also raises ethical dilemmas, that will have to be addressed before it is rolled out. Imagine that someone got a positive result but further investigations revealed nothing, he says. You cant put that kind of psychological burden on a patient.

The jury is out on whether its possible to wind back the epigenetic clock. This question is the subject of serious inquiry, but many researchers worry that as a wave of epigenetic cosmetics hits the market, people are parting with their money on the basis of scientifically unsupported claims. Science has only scratched the surface of the epigenome, says Flanagan. The speed at which these things happen and the speed at which they might change back is not known. It might be the fate of every young science to be misunderstood. Thats still true of epidenetics, but it could about to change.

Until recently, sequencing the epigenome was a relatively slow and expensive affair. To identify all the methyl tags on the genome, for example, would require two distinct sequencing efforts and a chemical manipulation in between. In the past few years, however, it has become possible to sequence the genome and its methylation pattern simultaneously, halving the cost and doubling the speed.

Oxford Nanopore Technologies, the British company responsible for much of the tracking of the global spread of Covid-19 variants, which floated on the London Stock Exchange last week, offers such a technology. It works by pushing DNA through a nanoscale hole while current passes either side. DNA consists of four bases or letters A, C, G and T and because each one has a unique shape in the nanopore it distorts the current in a unique and measurable way. A methylated base has its own distinctive shape, meaning it can be detected as a fifth letter.

The US firm Illumina, which leads the global DNA sequencing market, offers a different technique, and chemist Shankar Balasubramanian of the University of Cambridge has said that his company, Cambridge Epigenetix, will soon announce its own epigenetic sequencing technology one that could add a sixth letter in the form of hydroxymethyl tags.

Protein modifications still have to be sequenced separately, but some people include RNA modifications in their definition of epigenetics and at least some of these technologies can detect those too meaning they have the power to generate enormous amounts of new information about how our genetic material is modified in our lifetime. Thats why Ewan Birney who co-directs the European Bioinformatics Institute in Hinxton, Cambridgeshire, and who is a consultant to Oxford Nanopore, says that epigenetic sequencing stands poised to revolutionise science: Were opening up an entirely new world.

The rest is here:
Epigenetics, the misunderstood science that could shed new light on ageing - The Guardian

Classical genetics and traditional breeding in cucumbers – hortidaily.com

Rapid progress has been made in classical genetics and traditional breeding in cucumber for various quantitative and qualitative traits which greatly benefited the development of superior varieties suitable for open field and protected cultivation. The different breeding methods like plant introductions, hybridizations, pedigree selection, recombination breeding, and marker-assisted selection have been employed successfully in developing superior varieties and F 1 hybrids.

The development of new varieties with earliness, high yield, and resistance to diseases (powdery mildew, downy mildew, and tolerance to the virus) through a selection of superior parental lines followed by hybridization and marker-assisted introgression of desired genes was a game-changer in cucumber breeding. The exploitation of gynoecious sex along with parthenocarpic traits in traditional breeding has created a revolution in cucumber cultivation throughout the world which enabled the adoption of cucumber crops by the farming communities on a large scale.

Molecular markers technology could be exploited to overcome the obstacle of traditional breeding by accelerating the breeding cycle and selection of desirable traits. The high-density genetic maps for various traits have been constructed in cucumber to detected quantitative traits loci (QTLs) for genetic enhancement in different market classes of cucumber. Therefore, this research highlights the concepts of genetic foundations for advancement made in cucumber breeding.

Read the complete research at http://www.researchgate.net.

Jat, Gograj & Behera, Tusar & Lata, Suman. (2021). Classical Genetics and Traditional Breeding in Cucumber (Cucumis sativus L.). 10.5772/intechopen.97593.

Excerpt from:
Classical genetics and traditional breeding in cucumbers - hortidaily.com

CDC, ClinGen Partner to Develop Curated List of Important Variants for Use in NGS Genetic Testing – GenomeWeb

NEW YORK The Centers for Disease Control and Prevention said on Monday that its Genetic Testing Reference Materials Program (GeT-RM) has partnered with the Clinical Genome Resource (ClinGen) to develop a publicly available list of 546 curated clinically important variants in 84 genes for use in next-generation sequencing genetic testing.

By defining variants that are either major contributors to disease or difficult to detect, the list will serve as a resource for the design of comprehensive analytical validation studies, as well as the creation of computer-modulated or simulated reference materials for clinical genomic test development, the partners said.

Genetic testing has grown from the analysis of small sets of known pathogenetic variants in one or a few genes to the analysis of hundreds or thousands of genes simultaneously using NGS, they added. But it's difficult, or even impossible, to obtain DNA reference materials containing the full scope of variants and variant types needed to perform a comprehensive validation study. It can also be challenging for laboratories to maintain the expert knowledge to identify variants that are appropriately representative of the spectrum of disease for inclusion in validation studies.

The new variant list, they said, will help address these complexities.

The CDC and ClinGen first proposed the curated list in a paper published in August in the Journal of Molecular Diagnostics. The variant types include 346 SNVs, 104 deletions, 37 copy number variants, 25 duplications, 18 deletion-insertions, five inversions, four insertions, two complex rearrangements, three difficult-to-sequence regions, and two fusions. They were nominated for a variety of reasons, including being major contributors to disease, analytically difficult to detect, or inadvertently filtered out due to high allele frequency.

The authors also noted that the list of 84 genes include 29 of the 73 genes recommended by the American College of Medical Genetics and Genomics for reporting of incidental or secondary findings.

The ClinGen Allele Registry was used to standardize nomenclature for all nominated variants, and ClinVar Variation IDs and associated disorders were added where available. The Food and Drug Administration has also recognized ClinGen's curation process and its resulting classifications as a regulatory-grade variant database, and the curated variants are available via the National Center for Biotechnology Information's ClinVar database and ClinGen's Evidence Repository.

"This important novel approach will remove a critical bottleneck for test developers and may help harmonize test development and validation across laboratories," co-lead investigator Birgit Funke, VP of genomic health at Sema4, said in a statement.

Co-lead investigator and GeT-RM Director Lisa Kalman also noted that the partners have started a pilot project to demonstrate how the curated variants "could be used to create reference materials by in silico mutagenesis of NGS sequencing files. The pilot will examine whether the added variants can be detected by the clinical laboratories that generated the NGS files and demonstrate a general process that labs can use to develop electronic reference materials to fit their own needs."

GeT-RM and ClinGen will continue to add to the current variant list as needed, and are inviting input from the genetics community about the list and the processes used to generate it.

Visit link:
CDC, ClinGen Partner to Develop Curated List of Important Variants for Use in NGS Genetic Testing - GenomeWeb

What Can Genetics Tell Us About the Molecular Features of a Bladder Cancer Tumor? – SurvivorNet

Genetic Testing and Bladder Cancer

Genes are the basic units of inheritance in all living organisms. They provide cells with the necessary information for normal functioning, but they can be altered by the same environmental factors that cause cancer to develop.

Genetic testing helps identify specific genes that have mutated or been altered in a way that causes normal cells to become cancerous. These results are used by healthcare providers to predict responses to various types of treatment and monitor the progress of the disease. Genetic testing can refer to both germline testing (mutations in cells without cancer ) and also somatic testing of a patients tumor (mutations in cells with cancer).

Genetic testing is one of the most important things we can counsel patients about, says Dr. Arjun Balar, medical oncologist and assistant professor of medicine at the Perlmutter Cancer Center at NYU Langone Health.

What genetic testing means is understanding in a comprehensive way all the genetic abnormalities that may be present in one patients cancer that may not be present in others.

When examining genetic changes within tumor cells, researchers look for two main things:

These genetic abnormalities are what researchers are beginning to use as biomarkers for predicting patient responses to different forms of treatment.

In some families, bladder cancer occurs at higher rates than in the general population. In these cases, careful examination of the genealogy may reveal specific mutations passed from parent to child that may lead a medical provider to suspect one of the hereditary forms of bladder cancer. Some germline mutations linked to bladder cancer include:

While its possible, inherited gene mutations arent as commonly associated with bladder cancer as they are with other types of cancer, such as breast and ovarian. Sometimes, bladder cancer may occur in families because of toxic chemical or environmental exposures.

There are certain factors that increase an individuals risk for developing bladder cancer even if no family history exists. These include smoking and exposure to specific chemicals over long periods of time.

There are also inherited genetic syndromes that may place an individual at greater risk for developing bladder cancer. These include:

If genetic testing reveals you lack certain genes mutated in bladder cancer, you may be less likely to respond to certain treatments. These include targeted therapies, immunotherapies and chemotherapy drugs.

Genetic testing is not the only factor that determines your response to certain treatments. Even if your bladder cancer has all the genetic mutations that predict response to certain treatments, it still may not respond to them, because genetics is only one factor in determining a treatments effectiveness.

To increase the likelihood of response, bladder cancer treatments need to be combined with interventions designed to help your immune system target and kill cancer cells.

Genetic testing may also inform some decisions you and your medical team make as part of your ongoing care. If you are planning additional treatment after surgery or radiation, genetic testing may help determine the most appropriate treatment to use.

Genetic testing may be beneficial for many people with cancer. However, no guidelines exist to determine who should get genetic testing and the type of testing that should be done.

When I counsel a patient whos now undergoing their first treatment for advanced bladder cancer, Ill often encourage them to undergo genetic testing, mainly because we may find a genetic marker that is present in their cancer that might help me direct them toward a specific clinical trial that involves a drug that is specific for their genetic mutation, explains Dr. Balar.

Dr. Balar also recommends genetic testing for any patient with stage II or greater cancer. I advocate for early testing to have that information available early on so that if its needed, that information is readily available to make treatment decisions.

If youve been diagnosed with bladder cancer, talk to your healthcare team about the benefits and limitations of genetic testing.

Learn more about SurvivorNet's rigorous medical review process.

Lindsay Modglin is a freelance writer. Read More

Genetic testing helps identify specific genes that have mutated or been altered in a way that causes normal cells to become cancerous. These results are used by healthcare providers to predict responses to various types of treatment and monitor the progress of the disease. Genetic testing can refer to both germline testing (mutations in cells without cancer ) and also somatic testing of a patients tumor (mutations in cells with cancer).

What genetic testing means is understanding in a comprehensive way all the genetic abnormalities that may be present in one patients cancer that may not be present in others.

When examining genetic changes within tumor cells, researchers look for two main things:

These genetic abnormalities are what researchers are beginning to use as biomarkers for predicting patient responses to different forms of treatment.

In some families, bladder cancer occurs at higher rates than in the general population. In these cases, careful examination of the genealogy may reveal specific mutations passed from parent to child that may lead a medical provider to suspect one of the hereditary forms of bladder cancer. Some germline mutations linked to bladder cancer include:

While its possible, inherited gene mutations arent as commonly associated with bladder cancer as they are with other types of cancer, such as breast and ovarian. Sometimes, bladder cancer may occur in families because of toxic chemical or environmental exposures.

There are certain factors that increase an individuals risk for developing bladder cancer even if no family history exists. These include smoking and exposure to specific chemicals over long periods of time.

There are also inherited genetic syndromes that may place an individual at greater risk for developing bladder cancer. These include:

If genetic testing reveals you lack certain genes mutated in bladder cancer, you may be less likely to respond to certain treatments. These include targeted therapies, immunotherapies and chemotherapy drugs.

Genetic testing is not the only factor that determines your response to certain treatments. Even if your bladder cancer has all the genetic mutations that predict response to certain treatments, it still may not respond to them, because genetics is only one factor in determining a treatments effectiveness.

To increase the likelihood of response, bladder cancer treatments need to be combined with interventions designed to help your immune system target and kill cancer cells.

Genetic testing may also inform some decisions you and your medical team make as part of your ongoing care. If you are planning additional treatment after surgery or radiation, genetic testing may help determine the most appropriate treatment to use.

Genetic testing may be beneficial for many people with cancer. However, no guidelines exist to determine who should get genetic testing and the type of testing that should be done.

When I counsel a patient whos now undergoing their first treatment for advanced bladder cancer, Ill often encourage them to undergo genetic testing, mainly because we may find a genetic marker that is present in their cancer that might help me direct them toward a specific clinical trial that involves a drug that is specific for their genetic mutation, explains Dr. Balar.

Dr. Balar also recommends genetic testing for any patient with stage II or greater cancer. I advocate for early testing to have that information available early on so that if its needed, that information is readily available to make treatment decisions.

If youve been diagnosed with bladder cancer, talk to your healthcare team about the benefits and limitations of genetic testing.

Learn more about SurvivorNet's rigorous medical review process.

Lindsay Modglin is a freelance writer. Read More

Original post:
What Can Genetics Tell Us About the Molecular Features of a Bladder Cancer Tumor? - SurvivorNet

Arrhythmia: Is It a Genetic Condition? – Healthline

You inherit a lot of things from your parents, including the color of your eyes and how tall you will be. But not every genetic trait is a good one.

An arrhythmia is one example of a genetic health condition. These can also be called inherited or familial conditions.

While sudden cardiac death is extremely rare, affecting just 3 in every 100,000 people, a 2011 study found that about 70 percent of people under 40 who died from sudden cardiac issues had underlying heart arrhythmias that they inherited. This means that the issue with the hearts ability to beat regularly was passed on by one or both parents.

Sometimes, the issue is limited to a malfunction in the electrical signals in the heart, the American Heart Association says. But in about a third of cases, arrhythmias can develop because of structural issues, or the way the heart is formed.

Your heart operates using a complex electrical system that pulses through a detailed and delicate structure. Any time one of these electrical signals is off, or a part of the structure is damaged or formed incorrectly, it can create a host of issues.

Experts divide inherited heart arrhythmias into two categories:

All inherited heart arrhythmias are considered to be relatively rare conditions, but the most common types are:

Read on to learn about the main types of inherited heart arrhythmias.

Atrial fibrillation, also known as AFib or AF, is the most common type of heart arrhythmia overall. This condition involves the top chambers of the heart, which are known as the right and left atria.

In AFib, the right and left atria quiver and are not coordinated in pumping. This leads to compromised blood flow to the lower chambers of the heart, or the right and left ventricles.

AFib can cause blood to pool in the atria. This increases your chance of developing blood clots, which are potentially life threatening. A 2016 study estimated that up to a third of all strokes that occur in people ages 65 and older are due to AFib.

This condition can develop with age, but recent studies have found that up to 30 percent of people with AFib inherited it. According to MedlinePlus Genetics, several genes have been linked to the development of familial AFib:

Many of these genes provide instructions as your heart forms on how its electrical channels should be wired. If these channels arent wired correctly, then ions tiny particles with an electrical charge will have trouble passing signals through the muscles of your heart.

Brugada syndrome is another type of electrical issue in the heart that causes the ventricles to beat irregularly or too fast. When this happens, your heart cant pump blood out to the body effectively.

This can cause serious difficulties since many of your organs rely on a consistent and strong blood flow to work properly. In severe cases, Brugada syndrome can cause ventricular fibrillation, a potentially life threatening irregular heart rhythm.

A 2016 study showed that at least 23 genes are associated with this syndrome. The primary ones are:

This is a rare form of inherited arrhythmia. People with catecholaminergic polymorphic ventricular tachycardia (CPVT) will experience a very fast heart rhythm during physical activity, called ventricular tachycardia.

In CPVT, ventricular tachycardia usually happens during some form of exercise. Sometimes you can notice it before ventricular tachycardia occurs. You can do this by observing symptoms known as ventricular premature contractions (VPCs) during exercise.

With this type of genetic arrhythmia, the structure of the heart is usually unaffected. It typically appears in people 40 years and younger.

Specific genes linked to this condition are:

MedlinePlus Genetics says that RYR2 mutations account for about half of CPVT cases, while CASQ2 causes only about 5 percent. Both these genes are responsible for making proteins that help keep your heartbeat regular.

With this condition, the muscles that cause the heart to contract, or beat, take too long to recharge between pumps. This can upset the timing and regularity of your heartbeat, leading to other issues. While long QT syndrome can be caused by medications or other heart conditions, it can be inherited for many.

A 2016 study found that 15 genes are associated with this condition, but the most common are:

Most of the genes linked to familial arrhythmias are autosomal dominant, but some autosomal recessive disorders can cause long QT syndrome too. Genes KCNQ1 and KCNE1 are linked to rarer types of long QT syndrome called Jervell and Lange-Nielsen syndromes. In addition to inherited arrhythmias, people with these conditions also experience deafness.

This is an uncommon type of inherited arrhythmia. According to MedlinePlus Genetics, only about 70 cases of short QT syndrome have been diagnosed since it was recognized in 2000. Many more cases may exist, but they havent been diagnosed because this syndrome can occur without any symptoms.

With this condition, the heart muscle doesnt take long enough to charge between beats. This can cause no symptoms at all in some people. But in others, its the cause of sudden cardiac arrest or death.

Genes linked to this condition include:

With this rare condition, the heart has both structural and electrical issues. Electrical issues come in the form of a long QT interval, or the time it takes the heart to charge after each beat.

A long QT interval can lead to ventricular tachycardia, an often fatal arrhythmia. Ventricular tachycardia is the cause of death in about 80 percent of people with this syndrome.

Since this syndrome can also affect other parts of the body like the nervous system and immune system, many people with Timothy syndrome die during childhood. Its an autosomal dominant syndrome, meaning only one copy of an altered gene can lead to it. But because few people with Timothy syndrome survive into adulthood, its not usually passed from parent to child.

Instead, Timothy syndrome usually develops because of new mutations in the CACNA1C gene. This gene helps to manage the flow of calcium ions through heart muscles, affecting the regularity of your heartbeat.

Another issue with the hearts electrical system, Wolff-Parkinson-White syndrome occurs when an extra pathway for signals forms in the heart. This means that electrical signals can skip over the atrioventricular node, the part of the heart that helps control your heart rate.

When electrical signals skip over this node, it can cause your heart to beat extremely fast. This results in an arrhythmia called paroxysmal supraventricular tachycardia.

In some cases, this syndrome has been passed on through families. But most people who develop this condition have no family history. Also, for many people with this syndrome, the cause is unknown. A few cases are the result of mutations in the PRKAG2 gene.

This rare condition is primarily a structural issue. If you have this condition, a genetic mutation causes the muscle cells in your right ventricle the lower chamber of the heart to die. The condition mostly develops in people under age 35.

Arrhythmogenic right ventricular dysplasia usually develops with no symptoms at all. But it can still cause irregular heartbeats and even sudden death, especially during exercise. In later stages, this condition can also lead to heart failure.

Roughly half of all cases of arrhythmogenic right ventricular heart failure run in families. Autosomal dominant transmission from one parent is most common. But it can be passed on as an autosomal recessive gene from both parents, too. At least 13 genetic mutations have been connected to this disorder. PKP2 appears to be one of the most commonly affected genes.

Genes that cause this condition are responsible for forming desmosomes, or structures that connect muscle cells in the heart to each other. When these cells are not formed correctly, the cells that make up the muscles in your heart cant connect or communicate signals to one another.

Theres a lot of uncertainty around the cause of idiopathic ventricular fibrillation. Many people who are diagnosed with this condition have survived a cardiac arrest with ventricular fibrillation and no other obvious causes. A genetic cause has been proposed in a 2016 study, but research is ongoing.

Idiopathic means that a conditions origins are unknown. As genetic testing for other familial arrhythmias improves, it seems as though cases of idiopathic ventricular fibrillation are going down.

See the article here:
Arrhythmia: Is It a Genetic Condition? - Healthline

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek – EurekAlert

video:A new GeneSight Mental Health Monitor national survey finds many Americans are experiencing anxiety symptoms, but some wont seek treatment. view more

Credit: GeneSight Mental Health Monitor

Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they wont seek treatment for mental health conditions and others say they wont get help until these symptoms take a toll in their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months, according to the GeneSight Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine.

Of those surveyed who are diagnosed with anxiety, the numbers are even worse 86% rated their anxiety symptoms as moderate to severe over the past six months. While the pandemic is only 18 months old, more than half of those diagnosed with anxiety say they lived with symptoms for years or decades before seeking treatment.

For those who havent sought treatment but are concerned they may be suffering from anxiety, only 36% are planning to seek treatment. When asked what it would take to get help for their anxiety, 47% said a debilitating panic attack. Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%).

Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldnt wait to seek treatment, said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon. If you are afraid to go out, experiencing panic attacks, cant sleep, or your relationships are suffering, you dont have to live like this. You don't have to wait. You don't have to suffer for years. Help is out there and treatment can help.

The impact of COVID on anxiety

Many American adults expressed concern regarding how the pandemic has impacted their mental health:

Mental health conversation is shifting

Of those diagnosed with anxiety, nearly half said they would feel more comfortable talking about their mental health today than they would a year ago.

The pandemic appears to have made people willing to share their mental health struggles, said Mark Pollack, MD, chief medical officer for Mental Health at Myriad Genetics. Talking about mental health challenges is the first step towards getting treatment.

Mental health disorders should be treated

While more people appear to be willing to talk about their mental health, one out of five respondents still say they wont seek treatment. The top reasons for those who would NOT seek treatment for a mental challenge are:

Untreated anxiety can be associated with distressing and disabling panic attacks, intense worry, and disruption to your life, work and relationships, said Dr. Pollack. Like other medical conditions, individuals should seek evaluation and treatment as early as possible, to minimize the distress and dysfunction associated with these conditions.

Anna, a 32-year-old mother who was first diagnosed with anxiety in her early 20s, said that seeking treatment wasnt easy. She went through an extensive trial-and-error period with different medications and dosages.

Medication seems to work fast in my body, so after taking a medication that was supposed to help me, my anxiety would instead get worse I would have suicidal thoughts and be paralyzed with worry, said Anna. My doctor would increase the dosage or change medications, which would lead to horrible side effects.

Anna then took the GeneSight test, which analyzes how a patients genes may affect their outcomes with medications commonly prescribed to treat anxiety, depression, ADHD, and other psychiatric conditions.

After reviewing the results of my test, my psychiatrist reduced the dose by half, and it helped me. I honestly dont know if I would have taken another medication if it hadnt been for genetic testing, said Anna. Im glad I pursued treatment until I found a medication and dosage that worked for me. Now that Im not riddled with crippling anxiety, everything has gotten better. Im a better mom. Im more motivated, more outgoing and friendly.

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visit GeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visit https://bit.ly/2Y4qGri.

About the GeneSight Mental Health Monitor

The GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted by ACUPOLL Precision Research, Inc. in Aug.-Sept. 2021 among a statistically representative sample of adults age 21+, including a representative sample diagnosed with anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 61 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

See the rest here:
Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek - EurekAlert

Genetics scientist: No new covid19 variant in Trinidad and Tobago – TT Newsday

NewsRia Chaitram2 Days AgoProfessor Christine Carrington -

A genetics scientist has dismissed claims that there were new covid19 variants in Trinidad and Tobago and by extension the rest of the Caribbean.

At the ministrys covid19 media conference on Saturday morning, professor of molecular genetics and virology at the University of the West Indies (UWI) campus in St Augustine, Christine Carrington said the claims of an undetermined strain stemmed from inaccurate reports on social media.

In September, reports coming out of Grenada suggested that there was an undetermined covid19 variant, which was attributable to its rise in cases in mid-August.

The claims said samples from Grenada as well as Barbados sent to the Caribbean Public Health Agency (CARPHA) for testing came back undetermined and further genome sequencing and analysis were needed.

Carrington said, I can assure that no undetermined variant was discovered among the samples from Grenada or Barbados when sent to Trinidad for home genome sequencing.

I am absolutely certain about this because it is my lab at UWI that does the sequencing and I report the results, myself, to CARPHA and to the Ministry of Health.

She described the claims as erroneous and said it came about because of a misinterpretation of the genome sequencing results.

Genome sequencing is like putting together a jigsaw puzzle, if you are able to extract enough pieces of the virus genetic information from a sample and, work out the position of the virus genome, then you can work out what lineage you are looking at, and whether it is a variant of concern.

Sometimes samples are not of sufficient quality to get enough pieces of that puzzle, to build enough of a picture to work out which lineage the virus belongs to. In those cases, to determine if it is a variant of concern, you cannot say yes or no because you do not have enough information, she explained.

As such, Carrington said, the low quality of the samples taken from Grenada and Barbados, was unable to show the lineage of the virus, which meant the results were undetermined and not that there was an undetermined variant.

She explained that home genome sequencing revealed the detailed structure of the virus and the only way to characterise new variants, while PCR testing was done to determine if the virus was present in a person, and they should not be confused.

When the matter was first detected and reported in September, the Pan-American Health Organization (PAHO) also dismissed the claim.

It said, Our specialists have confirmed with the laboratory involved that a result from the samples in Grenada could not be determined due to their low quality and not due to an undetermined variant.

Carrington added that in TT, the covid19 variants of concern were present were alpha, gamma and delta, in which gamma and delta were evidenced to be spread at community level and alpha was not.

The mu and lambda variants, she said were not detected in TT, but detected in other regional countries.

Read more here:
Genetics scientist: No new covid19 variant in Trinidad and Tobago - TT Newsday

How a Venture Investor with a PhD in Genetics Helped This Biotech Firm Get Started, Funded, and Acquired – Inc.

IN 2016, INVENTOR and scientist Erik Gentalen reached out to a former colleague with exciting news, and a proposition.

"I started a company, and we could use some help," Gentalen said. The former colleague, Lena Wu, had worked with him around 15 years earlier as the director of business development at Caliper Technologies, a Mountain View, California-based bioresearch firm. Gentalen's new company, Intabio, would launch his latest invention, an instrument to analyze and ensure the efficacy and safety of biopharmaceutical drugs. Called the Blaze System, the machine could reduce the analysis time from weeks in some cases to less than 30 minutes per sample, dramatically shortening a drug's development period.

Wu joined Intabio's board later that year and became CEO the next. It was a hire that paid dividends in unexpected ways. When it came time to raise startup capital, Gentalen turned to Genoa Ventures managing director Jenny Rooke, whom he'd met through other investors in the life sciences industry.

"It was Erik's openness to bringing in Lena's complementary strengths that attracted me to the company," Rooke says. "When Lena joined forces with Erik as his business partner and Intabio's CEO, I knew the time was right."

In 2017, Rooke's San Francisco-based venture capital firm led Intabio's $3.2 million seed financing.

"It was clear from the earliest meeting that Jenny had great technical expertise, was willing to be collaborative in solving issues, and was thoughtful and strategic," Wu says. "Many people in Jenny's position are super supportive but not critical. She's the rare combination of both."

Rooke honed her expertise while earning a PhD in genetics at Yale, after which she worked at McKinsey advising pharmaceutical and biotech companies on business strategy. She also served in the executive ranks of U.S. Genomics (later called PathoGenetix), leading R&D and corporate development. Rooke knew the business. According to Wu, she had a keen eye for burnout, a common affliction among entrepreneurs. "She would say, 'You need to take a break. Now, go on vacation,' " Wu recalls. "I've never had another VC tell me to go on vacation."

Though Genoa didn't lead Intabio's Series A or Series B funding rounds, which brought the company's total funding to $30 million, Rooke introduced Wu to other investors and identified VCs to target. "We gained a great deal of credibility as a good investment given Jenny's reputation and the fact that she led our seed round," Wu says.

Intabio's first non-founder hire after raising capital was principal scientist Scott Mack, who helped develop the company's technology and was the first author of the company's published scientific paper describing the technology. (Mack's dog is also the Blaze System's namesake.) As of early 2021, Intabio had more than 40 employees.

Mack and Blaze (the system, not the dog) had their work cut out for them. Getting from a prototype that was tested only in-house at Intabio to a pre-commercial beta system took three years of development. Pharmaceutical companies Pfizer and Janssen Pharmaceuticals beta-tested the Blaze system, while Merck was an "early access collaborator" that sent samples to Intabio to analyze at the company's lab and return the results. Wu developed Intabio's go-to-market strategy and early access program, with Rooke helping refine and pressure-test aspects of the strategy.

When all was said and done, the proof-of-concept method worked. In January 2021, the life sciences company Sciex announced it had acquired Intabio for an undisclosed sum, just three and half years after the startup began operations. And when negotiating the deal, Wu relied on Rooke to play the role of not just investor but true partner.

"Jenny's input was, as always, both supportive and rigorous," Wu says. "It gave me the confidence that as a management team, we were making the right decision."

From the October 2021 issue of Inc. Magazine

Continued here:
How a Venture Investor with a PhD in Genetics Helped This Biotech Firm Get Started, Funded, and Acquired - Inc.

The Multiple System Atrophy Coalition Announces a Groundbreaking Project to Explore the Genetics of MSA – Johnson City Press (subscription)

MCLEAN, Va., Oct. 1, 2021 /PRNewswire-PRWeb/ --The Multiple System Atrophy ("MSA") Coalition announces a ground-breaking million-dollar multi-year collaborative project focused on exploring the genetics of up to 1,200 people with either a diagnosis of probable MSA, in the case of living patients, or postmortem pathological confirmation of multiple system atrophy, aimed at locating commonalities in their genes that might contribute to the development of multiple system atrophy. The aim of this collaborative study is to sequence and organize the genomes of existing genetic samples as well as to organize previously sequenced whole-genome data into a single database that is accessible to researchers worldwide. While many researchers have looked at the genetics of MSA, this will be the first time such a large number of genomes from ethnically diverse populations have been sequenced and organized in such a way as to facilitate thorough analysis and collaborative enterprise.

"MSA is not typically passed from parent to child, except in extremely rare cases. However, there are still important clues about the underlying cause of MSA that can be found by examining the genetic code of a large population of MSA patients and looking for commonalities. Because MSA is a such a rare disease, there is a need for multiple researchers to work together and pool their data. Until now there has not been a concerted effort among genetic labs to combine these rare genetic samples from MSA patients with diverse backgrounds into a large, shared database," said Pam Bower, chair of the MSA Coalition's research committee. "The MSA Coalition is proud to be the driver of this ground-breaking study."

University of Florida will perform genetic sequencing under the direction of Matt Farrer, PhD, while storage, analysis and visualization of data will occur at Harvard Medical School in the Clinical Genome Analysis Platform ("CGAP") under the direction of Dana Vuzman, PhD. Additional genomic information will be provided by University College of London, Queen Square Institute of Neurology under the direction of Henry Houlden, MBBS, MRCP, PhD; by Translational Genomics Research Institute (TGen) under the direction of Matt Huentelman, PhD (Funded in part by the Rex Griswold Foundation, a grant from the NIH NINDS (R21-NS093222, PI: Huentelman), and through institutional support of TGen.); and by Seoul National University, under the direction of Beomseok Jeon, MD, PhD and Han-Joon Kim, MD, PhD. The Core G team also plans to coordinate their work with that being done at NIH under the direction of Sonja Scholz, MD, PhD. The group, collectively known as "Core G" (Genetics), will work closely with Vik Khurana, MD, PhD, board member and Scientific Liaison of the Board of Directors of the MSA Coalition and Chief of the Movement Disorders Division at Brigham and Women's Hospital and Harvard Medical School. Dr. Khurana will endeavor to integrate Core G team-member efforts more broadly into the MSA Collaborative Cores Initiative sponsored by the Coalition that will seed fund additional projects over time.

"I am thrilled that after years of planning and deliberation that Core G is funded and ready to go," said Khurana. "This group of terrific researchers, together with their expertise, bring precious patient samples from three continents to establish a foundation upon which other collaborations and initiatives will be built. We are under no illusion that the genetics of MSA will prove challenging, no less than a moonshot. At the same time, genetic insights promise to unlock powerful hypothesis-driven science that can find cures. And so, this moonshot is worth the effort and has been structured to be collaborative, open and sustainable in the long-term."

"We are incredibly proud of assembling this group of world-renowned researchers to collaborate on this project. It has taken almost three years to organize this project and obtain consents from all the institutions involved. Great care has been taken by all contributing institutions to safeguard the privacy of the patients and anonymize the genetic materials, so that patient privacy is protected," said Cynthia Roemer, MSA Coalition board chair. "We are also grateful to our many donors, who have made this project possible, and to the patients we have lost to MSA who generously left bequests to the MSA Coalition to further critical research like this. We quite literally could not do it without them!"

Dana Vuzman, PhD is an Instructor of Medicine at Harvard Medical School and the Director of Genomic Platform Development at DBMI. Dr. Vuzman oversees the implementation of the Clinical Genome Analysis Platform (CGAP) and the Single Cell RNA Platform in the Department. Prior to joining DBMI, she served as Chief Informatics Officer at One Brave Idea, Sr. Director of Biomedical Informatics at KEW, Inc., and Co-Director at Brigham Genomic Medicine. Dr. Vuzman earned her PhD in Computational Biology from the Weizmann Institute of Science in Israel and completed her postdoctoral training in Computational Genetics at Brigham and Women's Hospital and Harvard Medical School.

Matt Farrer, PhD is critically acclaimed for his work in the genetics and neuroscience of Parkinson's disease. His inspiration to apply genetic analysis to complex neurologic disorders came from early work as a care assistant of patients and families with neurologic and psychiatric disorders. Dr. Farrer earned his first degree in Biochemistry with a Doctoral degree in Molecular and Statistical Genetics from St. Mary's Hospital Medical School, UK. He completed a fellowship in Medical Genetics at the Kennedy-Galton Centre, UK and in Neurogenetics at Mayo Clinic. Dr. Farrer became an Assistant Professor of Molecular Neuroscience in 2000 where he opened his first laboratory to predict and prevent Parkinson's disease. Dr. Farrer became a tenured professor in 2006, a Mayo Consultant, and subsequently, a Distinguished Mayo Investigator. In 2010, Dr. Farrer was awarded a Canada Excellence Research Chair to build the Centre for Applied Neurogenetics and Neuroscience at the University of British Columbia, Vancouver, Canada where he became a Professor of Medical Genetics. The Province of British Columbia subsequently awarded him the Don Rix Chair in Precision Medicine, and his team had many notable accomplishments including several new genes and mouse models for Parkinson's disease. The team also implemented high-throughput sequencing in pediatric seizure disorders and neonatology in clinical service. The former was funded through the Medical Services Plan of British Columbia and was a first for Canada.

In 2019, Dr. Farrer accepted an endowed chair at the Norman Fixel Institute for Neurological Diseases (thanks to a generous endowment from the Lauren and Lee Fixel Family Foundation). Dr. Matt Farrer also directs the UF Clinical Genomics Program. As such he currently has appointments and affiliations in the UF College of Medicine's Neurology and Pathology Departments, Clinical and Translational Science Institute, the Evelyn F. and William L. McKnight Brain Institute, the Center for Translational Research in Neurodegenerative Disease, and the Center for Neurogenetic in addition to the Norman Fixel Institute for Neurological Diseases.

Henry Houlden, MBBS, MRCP, PhD: Dr. Houlden is a professor of neurology and neurogenetics in the Department of Neuromuscular Disease, University College, London, Queen Square Institute of Neurology, and undertakes research laboratory works on neurogenetics and movement disorders with a particular interest in rare diseases that are adult or childhood-onset, such as multiple system atrophy (MSA), spinocerebellar ataxia and other movement disorders, inherited neuromuscular conditions, and difficult to diagnose disorders, particularly in diverse and underrepresented populations. He assists with the integration of new gene discovery with exome and genome sequencing identifying disease genes such as CANVAS, NARS1, NKX-6.2, SCA11, SCA15, GRIA2, and GAD1, with functional experimental validation in human tissue and other model systems. Dr. Houlden has clinical expertise in inherited neurological disorders and movement disorders such as multiple system atrophy, ataxia, leukodystrophy, epilepsy and paroxysmal conditions, spastic paraplegia and neuromuscular conditions.

Matt Huentelman, PhD: Dr. Huentelman's research interests center around the investigation of the "-omics" (genomics, transcriptomics, and proteomics) of neurological traits and disease. His laboratory's overarching goal is to leverage findings in these disciplines to better understand, diagnose, and treat human diseases of the nervous system.

Dr. Huentelman joined TGen in July of 2004 after completing his doctoral work at the University of Florida's Department of Physiology and Functional Genomics at the McKnight Brain Institute where he investigated the application of gene therapy in the study and prevention of hypertension. His undergraduate degree is in Biochemistry from Ohio University's Department of Chemistry and Biochemistry at Clippinger Laboratories. Dr. Huentelman's career includes visiting researcher stints in Moscow, Russia at the MV Lomonosov Moscow State University "Biology Faculty" and in the United Kingdom within the University of Bristol's Department of Physiology.

Beomseok Jeon, MD, PhD: Professor Jeon is the medical director of the Movement Disorder Center, Seoul National University Hospital and is interested in genetics of Parkinsonism and medical and surgical treatment of advanced Parkinson's Disease.

Dr. Jeon earned his undergraduate, MD and PhD degrees from Seoul National University. His clinical interests include Parkinson's disease and other movement disorders including tremor, ataxia, dystonia, and chorea. His research focuses on the role of genetics in movement disorders, especially in the Korean population. He has established a DNA bank of thousands of Korean patients with movement disorders and normal controls. He is also involved in treatment of advanced Parkinson disease, and works with neurosurgical colleagues for various surgical treatment.

Han-Joon Kim, MD, PhD: Dr. Kim is a Professor in the Department of Neurology and the Movement Disorder Center at Seoul National University Hospital, Seoul, Korea. After graduation from the Medical College of Seoul National University in 1997, Dr. Kim took an internship and residency in neurology at Seoul National University Hospital (SNUH) where he became a Movement Disorder Specialist.

Clinically, Dr. Kim has experience with patients with various movement disorders including Parkinson's Disease (PD), Multiple System Atrophy (MSA), other atypical Parkinsonisms, and ataxias. Notably, Dr. Kim has set up a large registry of Korean MSA patients, which will serve as a basis for both observational and interventional studies in this rare disease.

Sonja W. Scholz, MD, PhD: Dr. Scholz is a Neurologist and Neurogeneticist specialized in movement and cognitive disorders. She received her medical degree from the Medical University Innsbruck, Austria. Following graduation, she was a post-doctoral fellow at the Laboratory of Neurogenetics at the NIH's National Institute on Aging (NIA) under the supervision of Drs. Andrew Singleton and John Hardy. She obtained a Ph.D. in Neurogenomics from the University College London, UK in 2010. She then moved to Baltimore to complete her neurology residency training at Johns Hopkins. In 2015, Dr. Scholz received the McFarland Transition to Independence Award for Neurologist-Scientists. She is a Lasker Clinical Research Tenure Track Investigator within the Neurogenetics Branch at the NIH's National Institute of Neurological Disorders and Stroke (NINDS). Her laboratory focuses on identifying genetic causes of neurodegenerative diseases, such as dementia with Lewy bodies, multiple system atrophy, and frontotemporal dementia.

Media Contact

Moriah Meeks, MSA Coalition, +1 (312) 270-0171, mmeeks@staff.msacoalition.org

Facebook

SOURCE MSA Coalition

Visit link:
The Multiple System Atrophy Coalition Announces a Groundbreaking Project to Explore the Genetics of MSA - Johnson City Press (subscription)

Study finds genetic link between driving convictions, accidents and everyday behavior – News-Medical.Net

A new long-term psychological study of drivers has found an association between driving convictions, accidents and everyday behaviour such as eating junk food or alcohol consumption. The researchers have also uncovered evidence that this relationship is associated with genetic variation in serotonin metabolism the same neurotransmitter targeted by many antidepressants. This suggests that risky behaviour in driving and in life may have a common psychological basis.

In an innovative study, researchers from Professor Jaanus Harro's team at the University of Tartu (Estonia) combined psychological, genetic, and biochemical data from the unique Estonian Psychobiological Study of Traffic Behaviour with police and insurance records. 817 drivers (49.2% male, 50.8% female) participated in the study. Over a period of time they completed questionnaires to measure such factors as impulsivity and aggression: in addition, they underwent a series of blood tests and genetic analysis. Linking these results to the police and insurance databases the researchers began to uncover some of the links associated with risky driving. Presenting their findings to the ECNP Conference in Lisbon, they report that 137 drivers who had been cautioned for exceeding the speed limits tended to have faster reaction times, but that they also scored higher on physical and verbal aggression, undertaking more strenuous physical activity, and had higher consumption of junk foods (including energy drinks).

According to lead researcher Tnis Tokko:

"We were able to pick out lots of associations between everyday risk taking and risky driving. For example we found that subjects who drink energy drinks at least once a week were twice as likely to speed as those who didn't drink energy drinks as often. We think the energy drink consumption may be a related to a need for excitement, rather than the drinks themselves being a direct cause of traffic violations; the drivers' underlying psychological makeup may lead them both to speed, and to want to consume more energy drinks or junk food. Similarly, our psychological tests showed us that those with fast decision making skills were 11% more likely to speed, and those with higher excitement seeking were 13% more likely to speed".

He continued:

"Driving history is an excellent platform to study behavioural regulation; most people drive, and driving convictions or accidents are objective records - they remain in databases. We found that significant associations exist between risky traffic behaviour and a range of lifestyle behaviours, such as undertaking strenuous exercise, alcohol consumption, or junk food and energy drink consumption.

The researchers also looked at genetic traits in the volunteer drivers. They found that certain variants of a gene which controls serotonin transport (the 5-HTTLPR polymorphism) were associated with risky driving. Serotonin is the neurotransmitter which is thought to be involved in depression, and which is also regulated by many antidepressant drugs. "We found that certain gene variants are associated with risk-taking behaviour in both driving and in other areas of life; but this is an early finding and still needs to be confirmed" said Tnis Tokko.

The Estonian Psychobiological Study of Traffic Behaviour is a long-term study that started collecting data in 2001 it is believed to be the world's only long-term study to follow drivers while considering psychology, and the related biology. Initially it aimed to identify behaviour patterns of drunk drivers and speeding drivers to try to prevent these behaviours, but it has since expanded to consider other factors.

Tnis Tokko said "We are able to follow various driving-related factors over a period of years, including psychological behaviour, blood tests to understand biological changes, and genetics. We also have a firm idea of which of these drivers have committed traffic violations or have been in accidents. We believe this to be a unique system. This study shows that people who are reckless in traffic also tend to take chances in other areas of life, and our research shows that there may be a biological tendency to this behaviour".

Dr Oliver Grimm, senior psychiatrist at the University Clinic Frankfurt, commented:

"This study is very interesting, as it is already known from large registry studies that ADHD and traffic accidents are more common in adults. This specific study from Estonia now helps to better understand how this accident-prone group is constituted from both the genetic risk and personality traits."

Professor Oliver Howes, Professor of Molecular Psychiatry at King's College, London, said:

"This study adds to other work showing that psychological and biological traits are linked to how people behave in the world. It's important to recognise that the associations don't mean that one leads to the other"

Original post:
Study finds genetic link between driving convictions, accidents and everyday behavior - News-Medical.Net